PBI for Breast in Situ Carcinoma of Intermediate Low Risk As Local Adjuvant Treatment (PRISCILLA)
Partial Radiotherapy for Breast in Situ Carcinoma of Intermediate Low Risk As Local Adjuvant Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Screening and advances in breast imaging led to a continuous increase of Ductal Carcinoma in situ (DCIS) diagnosis. Unfortunately, the management of this specific disease is still debated regarding adjuvant therapy (radiation therapy and endocrine therapy) after breast conserving surgery (BCS).
Four randomized trials have shown a decrease of the local recurrence (LR) using adjuvant radiotherapy with conventional fractionation (50 Gy in 25 fractions). In the early breast cancer trialists' collaborative Group (EBCTCG) overview (7) radiotherapy approximatively halved the ipsilateral breast event (IBE) rate, from 28.1% to 12.9 % at 10 years. Radiotherapy was reported to be effective in reducing the risk of local recurrence in all analyzed patients and tumor characteristics (e.g. age, tumor size, histological grade, comedonecrosis, etc.), but no differences were seen in distant metastases, breast cancer-specific survival, or overall survival between irradiated and un-irradiated patients. Nowadays, progress in diagnosis and a greater attention in achieving negative surgical margins increased the interest in identifying sub groups of patient in which a treatment de-escalation could be possible. Some prospective randomized and non-randomized trials try to define a low-risk cohort in which radiotherapy could be omitted. RTOG 9804 randomized 711 low-intermediate risk patients to RT versus nothing and find that LF rate decreased significantly with the addition of RT.
De-escalation of radiation therapy treatment could be done with partial breast irradiation (PBI). In modern era 7 randomized trials analyzed the efficacy of PBI versus whole breast RT in low-risk patients with early stage breast cancer, using different techniques. Those studies drive ESTRO and ASTRO to endorse the use of PBI out of clinical trials. In general, PBI involves treating the surgical cavity with a 1- to 2-cm margin, thus reducing the volume of treated breast tissue by up to 50% using various methods. Technical approaches of PBI include multicatheter interstitial brachytherapy, balloon catheter brachytherapy, external 3-D conformal external beam radiotherapy (3D-CRT), intensity modulated radiotherapy (IMRT) and intraoperative radiotherapy (IORT). Park et al. reported a retrospective study on 53 patients treated with MammoSite brachytherapy or 3D-CRT, with a Three-year actuarial ipsilateral breast tumor recurrence was 2%. Becherini et al. analyzed the long-term efficacy and safety results of the series of 22 patients with DCIS enrolled in the accelerated PBI arm of the APBI-IMRT-Florence phase 3 trial and found 5- and 10-year local recurrence, distant metastasis-free survival, and breast cancer-specific survival of 100%.
To date, data from available literature supports the hypothesis that PBI is a safe well tolerated therapy that appears to be equivalent to WBI in terms of efficacy and ultimate breast cosmesis in infiltrating carcinoma. Data on DCIS are missing.
Based on this background, we designed a study to evaluate 5-year Local Control rate of Partial Breast Irradiated (PBI) using external beam radiotherapy (3D-CRT, VMAT-RA, Tomotherapy or Cyberknife) or brachytherapy in a selected group of women with low-intermediate DCIS.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- IRCCS Istituto Clinico Humanitas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age >40
Pathologically confirmed DCIS:
- low risk (lesions of ≤3 cm diameter, resection margins of at least 2 mm, nuclei grade: G1, G2)
- intermediate risk (lesions of ≤1 cm diameter, resection margins of at least 2 mm, nuclei grade: 3)
- Written informed consent
Exclusion Criteria:
- Prior thoracic radiation therapy
- Preoperative systemic treatments (i. e., chemotherapy, endocrine therapy);
- Autoimmune disease, vasculitis, collagenopathy or scleroderma that may predispose to late sequelae
- No other cancers in the last 5 years
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Partial Breast Irradiation
Radiation treatment will be started within 120 days after surgery. The fractionation schedule depends on the policy of the treating center, but is mandatory to use CT-based planning. Both once-daily and twice-daily schedule are allowed. The allowed schedules for external beams radiotherapy are:
The schedule for brachytherapy are:
|
External beam radiation therapy uses high doses of radiation to destroy cancer cells and shrink tumors. A large machine aims radiation at the cancer. The allowed schedules for external beams radiotherapy are:
Brachytherapy is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment. The schedule for brachytherapy are:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Local Control rate
Time Frame: 5 years
|
Absence of the occurrence of new lump in the irradiated breast or appearance of skin lesions; it will be divided in inside or outside the treated area, evaluating the localization in the breast.
For the evaluation it will be used bilateral mammography.
|
5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
toxicities assessed by "Common Terminology Criteria for Adverse Events (CTCAE) v5.0"
Time Frame: 5 years
|
Evaluation of toxicities due to partial breast irradiation, toxicities grade and specific term will be given using "Common Terminology Criteria for Adverse Events (CTCAE) v5.0".
|
5 years
|
|
The Harvard Scale
Time Frame: 5 years
|
aesthetic evaluation after partial breast irradiation.
Cosmesis will be evaluated using The Harvard Scale of cosmetic outcome.
The results will be % of the 4 possible outcomes (Excellent, Good, Fair, Poor)
|
5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3271
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.